Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1578-1584

  Barchiesi, Francesco ^a   Calabrese, David ^b   Sanglard, Dominique ^b   Di Francesco, Luigi Falconi ^a   Caselli, Francesca ^a   Giannini, Daniele ^a   Giacometti, Andrea ^a   Gavaudan, Stefano ^c   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL UMBRIA E DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; TERBINAFINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA TROPICALIS; FEMALE; FUNGUS CULTURE; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANIMALS; CANDIDA; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; GENE EXPRESSION REGULATION, FUNGAL; MICE; VIRULENCE;

EID: 0034075720     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1578-1584.2000     Document Type: Article

References (39)

1. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
2. Barchiesi, F., D. Arzeni, M. S. Del Prete, A. Sinicco, L. Falconi Di Francesco, M. B. Pasticci, L. Lamura, M. M. Nuzzo, F. Burzacchini, S. Coppola, F. Chiodo, and G. Scalise. 1998. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J. Antimicrob. Chemother. 41:541-548.
3. Barchiesi, F., A. L. Colombo, D. A. McGough, A. W. Fothergill, and M. G. Rinaldi. 1994. In vitro activity of itraconazole against fluconazole-susceptible and -resistant isolates of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1530-1533.
4. Barchiesi, F., L. K. Najvar, M. F. Luther, G. Scalise, M. G. Rinaldi, and J. R. Graybill. 1996. Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob. Agents Chemother. 40:1317-1320.
5. Barchiesi, F., A. M. Tortorano, L. Falconi Di Francesco, M. Cogliati, G. Scalise, and M. A. Viviani. 1999. ln-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J. Antimicrob. Chemother. 43:295-299.
6. Becker, J. M., L. K. Henry, W. Jiang, and Y. Koltin. 1995. Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infect. Immun. 63:4515-4518.
7. Buckner, F. S., A. J. Wilson, T. C. White, and W. C. Van Voorhis. 1998. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. 42:3245-3250.
8. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
9. Chen, C., T. G. Turi, D. Sanglard, and D. J. Loper. 1987. Isolation of the Candida tropicalis gene for P450 lanosterol demethylase and its expression in Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun. 146:1311-1317.
10. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as system antifungal therapy. N. Engl. J. Med. 330:263-272.
11. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhäuser. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
12. Geber, A., C. A. Hitchocock, J. E. Swartz, F. S. Pullen, K. E. Marsden, K. J. Kwon-Chung, and J. E. Bennett. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39: 2708-2717.
13. Graybill, J. H., E. Montalbo, W. R. Kirkpatrick, M. F. Luther, S. G. Revankar, and T. F. Patterson. 1998. Fluconazole versus Candida albicans: a complex relationship. Antimicrob. Agents Chemother. 42:2938-2942.
14. Graybill, J. H., L. K. Najvar, J. D. Holmberg, and M. F. Luther. 1995. Fluconazole, D0870, and flucytosine treatment of disseminated Candida twpicalis infections in mice. Antimicrob. Agents Chemother. 39:924-929.
15. Hitchcock, C. A., K. Barett-Bee, and N. J. Russel. 1986. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J. Gen. Microbiol. 132:2421-2431.
16. Lopez-Ribot, J. L., R. K. McAtee, L. N. Lee, W. R. Kirkpatrick, T. C. White, D. Sanglard, and T. F. Patterson. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida alhicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 42:2932-2937.
17. Lopez-Ribot, J. L., R. K. McAtee, S. Perea, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 1999. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:1621-1630.
18. Marichal, P., H. Vanden Bossche, F. C. Odds, G. Nobels, D. W. Warnock, V. Timmerman, C. Van Broeckhoven, S. Fay, and P. Mose-Larsen. 1997. Molecular biological characterization of an azole-resistant Candida glabraia isolate. Antimicrob. Agents Chemother. 41:2229-2237.
19. Marr, K. A., C. N. Lyons, T. Rustad, R. A. Bowden, and T. C. White. 1998. Rapid, transient, fluconazole resistance in Candida albicans is associated with increased raRNA levels of CDR. Antimicrob. Agents Chemother. 42: 2584-2589.
20. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution susceptibility testing of yeasts. Approved Standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Odds, F. C. 1993. Resistance of yeasts to azole-derivative antifungals. J. Antimicrob. Chemother. 31:463-471.
22. Orozco, A. S., L. M. Higginbotham, C. A. Hitchcock, T. Parkinson, D. Falconer, A. S. Ibrahim, M. A. Ghannoum, and S. G. Filler. 1998. Mechanism of fiuconazole resistance in Candida knisei. Antimicrob. Agents Chemother. 42:2645-2649.
23. Pfaller, M. A., J. Rhine-Chalberg, S. W. Redding, J. Smith, G. Farinacci, A. W. Fothergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32: 59-64.
24. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, O. P. Dib, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1996. Detection and significance of fluconazoie resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 174:821-827.
25. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazoie by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
26. Rex, J. H., M. A. Pfaller, A. L. Barry, P. W. Nelson, and C. D. Webb. 1995. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazoie versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 39:40-44.
27. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal .susceptibility testing: conceptual framework and analysis of in vitro/in vivo correlation data for fluconazoie, itraconazole, and Candida infection. Clin. Infect. Dis. 24:235-247.
28. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazoie. Antimicrob. Agents Chemother. 39:1-8.
29. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 ianosterol 14-a-demethylase (CYP51A1) from azole-resistanl Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
30. Sanglard, D., F. Isher, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug transporter gene. Microbiology 143:405-416.
31. Sanglard, D., F. Isher, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
32. Sanglard, D., K. Kuchler, F. Isher, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
33. Vanden Bossche, H., P. Marichal, F, C. Odds, L. Le Jeune, and M.-C. Coene. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.
34. White, T. C. 1997. Increased mRNA levels of ERC16, CDR. and MDRI correlate with the increases in azole resistance in Candida albicans isolates from a human immunodeficiency virus-infected patient. Antimicrob. Agents Chemother. 41:1482-1487.
35. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant Ianosterol 14-α-demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
36. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
37. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.
38. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazote prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
39. Wingard, J. R., W. G. Merz, and R. Saral. 1979. Candida tropicalis: a major pathogen in immunocompromised patients. Ann. Intern. Med. 91:539-543.